Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine

被引：0

作者：

Stefania Bulotta

Marilena Celano

Giuseppe Costante

Diego Russo

机构：

[1] University “Magna Graecia” of Catanzaro,Department of Health Sciences

[2] Institut Jules Bordet Comprehensive Cancer Center,Endocrinology Clinic, Internal Medicine Department

来源：

Endocrine | 2016年 / 52卷

关键词：

Differentiated thyroid cancer; Radioiodine; Molecular targets; Re-differentiation strategies; Nanodevices;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.

引用

页码：214 / 221

页数：7

共 50 条

[41] Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
Kiyota, Naomi
Robinson, Bruce
Shah, Manisha
Hoff, Ana O.
Taylor, Matthew H.
Li, Di
Dutcus, Corina E.
Lee, Eun Kyung
Kim, Sung-Bae
Tahara, Makoto
THYROID, 2017, 27 (09) : 1135 - 1141
[42] A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
Meng, Chao
Song, Juanjuan
Long, Wen
Mu, Zhuanzhuan
Sun, Yuqing
Liang, Jun
Lin, Yansong
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[43] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
Lindner, C.
Dierneder, J.
Pall, G.
Pirich, C.
Hoffmann, M.
Raderer, M.
Becherer, A.
Niederle, B.
Lipp, R.
Lind, P.
Gallowitsch, H.
Romeder, F.
Virgolini, I.
NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
[44] Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
Weitzman, Steven P.
Sherman, Steven, I
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 253 - +
[45] Predictive factors of radioiodine refractory tumours in patients with metastatic differentiated thyroid cancer
Iizuka, Y.
Katagiri, T.
Ogura, K.
Itasaka, S.
Inoue, M.
Nakamura, K.
Mizowaki, T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S604 - S604
[46] Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
Brose, Marcia S.
Capdevila, Jaume
Elisei, Rossella
Bastholt, Lars
Fuehrer-Sakel, Dagmar
Leboulleux, Sophie
Sugitani, Iwao
Taylor, Matthew H.
Wang, Zhuoying
Wirth, Lori J.
Worden, Francis P.
Bernard, John
Caferra, Paolo
Colzani, Raffaella M.
Liu, Shiguang
Schlumberger, Martin
ENDOCRINE-RELATED CANCER, 2024, 31 (08)
[47] New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond
Wang, Emilie
Karedan, Tezo
Perez, Cesar A.
ANTI-CANCER DRUGS, 2015, 26 (07) : 689 - 697
[48] Treatment of radioiodine refractory high-differentiated thyroid cancer with lenvatinib.
Romanov, Ilya
Mudunov, Ali
Isaev, Pavel
Bychkov, Yury
Odzharova, Akgul
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49] Targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer (DTC)
Herceg, Davorin
Herceg, Gordana Horvatic
PERIODICUM BIOLOGORUM, 2014, 116 (04) : 399 - 407
[50] Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer
Gao, Luying
Lin, Yansong
Jiang, Yuxin
Li, Hui
Gao, Qiong
Xi, Xuehua
Wang, Ying
Yang, Xiao
Lai, Xingjian
Zhu, Shenling
Zhang, Xiaoyan
Zhao, Ruina
Zhang, Bo
MEDICINE, 2019, 98 (45) : e17876

← 1 2 3 4 5 →